Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB154 + Capecitabine + Oxaliplatin + Zimberelimab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB154 | AB-154|AB 154|Domvanalimab | Immune Checkpoint Inhibitor 149 TIGIT Antibody 19 | AB154 (domvanalimab) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A124). | |
Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
Zimberelimab | GLS-010|AB122|AB-122|GLS010 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05568095 | Phase III | AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Capecitabine + Oxaliplatin + Zimberelimab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221) | Active, not recruiting | USA | TUR | ROU | POL | LTU | ITA | ISR | HUN | GRC | GBR | FRA | ESP | CAN | BRA | AUS | ARG | 13 |